Literature DB >> 16963794

Mechanism of synergistic action following co-treatment with pramipexole and fluoxetine or sertraline in the forced swimming test in rats.

Zofia Rogóz1, Grazyna Skuza.   

Abstract

The aim of the present study was to examine the effect of combined treatment of male Wistar rats with pramipexole and fluoxetine or sertraline in the forced swimming test. The obtained results showed that co-treatment with pramipexole (0.1 mg/kg) and fluoxetine (10 mg/kg) or sertraline (5 mg/kg) (in doses inactive per se) exhibited antidepressant-like activity in the forced swimming test. Sulpiride (a dopamine D(2/3) receptor antagonist) and WAY 100635 (a 5-HT(1A) receptor antagonist), either being ineffective in the forced swimming test, inhibited the antidepressant-like effect induced by co-administration of pramipexole and fluoxetine or sertraline. However, SCH 23390 (a dopamine D(1) receptor antagonist) only partly did not alter the effect of pramipexole given jointly with antidepressant drugs; on the other hand, S 33084 (a dopamine D(3) receptor antagonist) only partly decreased (in a statistically insignificant manner) that effect. Moreover, progesterone and BD 1047 (a sigma(1) receptor antagonist) counteracted the antidepressant-like effect induced by co-administration of pramipexole and sertraline (but not pramipexole and fluoxetine). In that test, active behavior did not reflect the increases in general activity, since combined administration of pramipexole and fluoxetine or sertraline failed to enhance the locomotor activity of rats. None of the tested drugs (SCH 23390, sulpiride, S 33084, WAY 100635, BD 1047 and progesterone) - alone or in combination with pramipexole and fluoxetine or sertraline - changed locomotor activity. The results described in the present paper indicate that co-administration of pramipexole and fluoxetine or sertraline may induce a more pronounced antidepressive activity than does treatment with pramipexole alone, and that in addition to other mechanisms, dopamine D(2/3) and 5-HT(1A) receptors may contribute to the antidepressant-like activity of pramipexole and fluoxetine or sertraline in the forced swimming test in rats. Moreover, sigma(1) receptors may constitute one of the possible mechanisms by which co-administration of pramipexole and sertraline induces antidepressant-like activity in that test.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16963794

Source DB:  PubMed          Journal:  Pharmacol Rep        ISSN: 1734-1140            Impact factor:   3.024


  12 in total

1.  Does Sertraline Affect Hypothalamic Food Intake Peptides in the Rat Experimental Model of Chronic Mild Stress-Induced Depression?

Authors:  Hatice Solak; Z Isik Solak Gormus; Raviye Ozen Koca; Canan Eroglu Gunes; Selim Kutlu
Journal:  Neurochem Res       Date:  2022-01-26       Impact factor: 3.996

Review 2.  Sigma-1 Receptors in Depression: Mechanism and Therapeutic Development.

Authors:  Peng Ren; Jingya Wang; Nanxi Li; Guangxiang Li; Hui Ma; Yongqi Zhao; Yunfeng Li
Journal:  Front Pharmacol       Date:  2022-06-16       Impact factor: 5.988

Review 3.  Neuropeptide and sigma receptors as novel therapeutic targets for the pharmacotherapy of depression.

Authors:  Konstantinos A Paschos; Stavroula Veletza; Ekaterini Chatzaki
Journal:  CNS Drugs       Date:  2009-09       Impact factor: 5.749

4.  Involvement of the sigma1 (sigma1) receptor in the anti-amnesic, but not antidepressant-like, effects of the aminotetrahydrofuran derivative ANAVEX1-41.

Authors:  J Espallergues; P Lapalud; A Christopoulos; V A Avlani; P M Sexton; A Vamvakides; T Maurice
Journal:  Br J Pharmacol       Date:  2007-08-06       Impact factor: 8.739

5.  Sexually dimorphic serotonergic dysfunction in a mouse model of Huntington's disease and depression.

Authors:  Thibault Renoir; Michelle S Zajac; Xin Du; Terence Y Pang; Leah Leang; Caroline Chevarin; Laurence Lanfumey; Anthony J Hannan
Journal:  PLoS One       Date:  2011-07-08       Impact factor: 3.240

Review 6.  A new nosology of psychosis and the pharmacological basis of affective and negative symptom dimensions in schizophrenia.

Authors:  Costa Vakalopoulos
Journal:  Ment Illn       Date:  2010-05-06

7.  Study of a mechanism responsible for potential antidepressant activity of EMD 386088, a 5-HT6 partial agonist in rats.

Authors:  Magdalena Jastrzębska-Więsek; Agata Siwek; Anna Partyka; Lucyna Antkiewicz-Michaluk; Jerzy Michaluk; Irena Romańska; Marcin Kołaczkowski; Anna Wesołowska
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-04-23       Impact factor: 3.000

8.  Ropinirole and Pramipexole Promote Structural Plasticity in Human iPSC-Derived Dopaminergic Neurons via BDNF and mTOR Signaling.

Authors:  Ginetta Collo; Laura Cavalleri; Federica Bono; Cristina Mora; Stefania Fedele; Roberto William Invernizzi; Massimo Gennarelli; Giovanna Piovani; Tilo Kunath; Mark J Millan; Emilio Merlo Pich; PierFranco Spano
Journal:  Neural Plast       Date:  2018-02-04       Impact factor: 3.599

9.  Biochemical and Functional Characterization of the Trace Amine-Associated Receptor 1 (TAAR1) Agonist RO5263397.

Authors:  Stefano Espinoza; Damiana Leo; Tatyana D Sotnikova; Mohammed Shahid; Tiina M Kääriäinen; Raul R Gainetdinov
Journal:  Front Pharmacol       Date:  2018-06-21       Impact factor: 5.810

10.  Pharmacology and therapeutic potential of sigma(1) receptor ligands.

Authors:  E J Cobos; J M Entrena; F R Nieto; C M Cendán; E Del Pozo
Journal:  Curr Neuropharmacol       Date:  2008-12       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.